2025 India Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 India Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics Market globally, and with presence or collaborations relevant to India, include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, and Silence Therapeutics. Alnylam Pharmaceuticals is a leader in RNAi therapeutics with FDA-approved products and a strong global footprint, including strategic interests in emerging markets like India. Ionis Pharmaceuticals is a pioneer in antisense technology, focusing on rare and neurological diseases, and has entered global partnerships enhancing its presence, including collaborations that could impact India. Sarepta Therapeutics and Silence Therapeutics also contribute with innovative RNA-based therapies targeting serious genetic diseases.
In India specifically, the antisense and RNAi field is growing, driven by increased investment and clinical trials, although it faces challenges such as delivery technology development and regulatory environment. Indian companies like Biocon have started clinical trials for siRNA therapies in partnership with global firms like Quark Pharmaceuticals, indicating a trend of collaboration and technology transfer. The market size in India was approximately USD 91.2 million in 2023, projected to grow significantly by 2030. Global companies often engage in research partnerships or supply development platforms catering to the Indian biopharma industry, which is becoming an attractive location for outsourced innovation in RNAi/antisense therapeutics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics Market globally, and with presence or collaborations relevant to India, include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, and Silence Therapeutics. Alnylam Pharmaceuticals is a leader in RNAi therapeutics with FDA-approved products and a strong global footprint, including strategic interests in emerging markets like India. Ionis Pharmaceuticals is a pioneer in antisense technology, focusing on rare and neurological diseases, and has entered global partnerships enhancing its presence, including collaborations that could impact India. Sarepta Therapeutics and Silence Therapeutics also contribute with innovative RNA-based therapies targeting serious genetic diseases.
In India specifically, the antisense and RNAi field is growing, driven by increased investment and clinical trials, although it faces challenges such as delivery technology development and regulatory environment. Indian companies like Biocon have started clinical trials for siRNA therapies in partnership with global firms like Quark Pharmaceuticals, indicating a trend of collaboration and technology transfer. The market size in India was approximately USD 91.2 million in 2023, projected to grow significantly by 2030. Global companies often engage in research partnerships or supply development platforms catering to the Indian biopharma industry, which is becoming an attractive location for outsourced innovation in RNAi/antisense therapeutics.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
